Bondronat

Bondronat

A brand name for IBANDRONIC ACID.
References in periodicals archive ?
The assessment affects nineteen centrally authorised medicines as well as various medicines that have been nationally authorised: Avastin, Bondenza, Bondronat, Bonviva, Cellcept, Fuzeon, Herceptin, Invirase, Mabthera, Mircera, Neorecormon, Pegasys, Roactemra, Tamiflu, Tarceva, Viracept, Xeloda, Xenical and Zelboraf.
Bisphosphonates include Aclasta, Actonel, Aredia, Bondronat, Boniva, Didronel, Fosamax, Fosavance, Reclast, Skelid and Zometa.
Recently announced data show that Bondronat (ibandronic acid) administered for the treatment of metastatic bone disease for 15 minutes has a safety profile consistent with the same dose of the drug administered during an hour.
Once approved as a 15 minute infusion, Bondronat will be the only bisphosphonate available in both short IV and oral formulations, and will thus offer a new consistency of care in the management of this devastating disease.
Bondronat, made by Roche, is used to treat breast cancer which has spread to the bone - also known as metastatic bone disease.
Bondronat can be taken as a pill, so patients can manage treatment without going into hospital.
Bondronat can be taken as a pill, meaning that patients can manage their treatment without having to go into hospital.
The arrival of Bondronat, made by Roche, was welcomed by campaigners and doctors.
Among the most promising prospects are CERA (Continuous Erythropoiesis Receptor Activator) for anemia, Bondronat for osteoporosis, the still-unnamed R450 for stress urinary incontinence (most common in women) and MRA for rheumatoid arthritis.
Approaching patent expiries for Bondronat and Zometa and the subsequent availability of cheaper generic versions may raise the barrier to uptake of more novel but costly emerging agents such as denosumab.
The Roche oncology portfolio also includes NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcaemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (hairy cell and chronic myeloid leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).
Other key products include NeoRecormon (anaemia in various cancer settings), Bondronat (prevention of skeletal events in breast cancer and bone metastases patients, hypercalcemia of malignancy), Kytril (chemotherapy and radiotherapy-induced nausea and vomiting) and Roferon-A (leukaemia, Kaposi's sarcoma, malignant melanoma, renal cell carcinoma).